Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $78.00 USD
Change Today -0.39 / -0.50%
Volume 4.2M
MDT On Other Exchanges
MDT is not on other exchanges.
As of 8:04 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

medtronic plc (MDT) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/25/15 - $79.50
52 Week Low
10/15/14 - $59.83
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDTRONIC PLC (MDT)

medtronic plc (MDT) Details

Medtronic plc manufactures and sells device-based medical therapies worldwide. The company’s Cardiac and Vascular Group segment offers pacemakers, implantable cardioverter defibrillators, implantable cardiac resynchronization therapy devices, AF products, diagnostics and monitoring devices, and remote monitoring and patient-centered software; and heart valves, percutaneous coronary intervention stent products, surgical valve replacement and repair products, endovascular stent grafts, and peripheral vascular intervention products. Its Minimally Invasive Therapies Group segment provides gastrointestinal diagnostics, ablation, and interventional lung solutions; stapling, vessel sealing, and other surgical instruments; sutures; electrosurgery products; hernia mechanical devices; mesh implants; products for patient monitoring and recovery, such as ventilators, capnography, and other airway products; sensors; monitors; compression and dialysis products; enteral feeding; wound care; and medical surgical products comprising operating room supply products, electrodes, needles, syringes, and sharps disposals. The company’s Restorative Therapies Group segment offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, and throat; systems that incorporate advanced energy surgical instruments; and image-guided surgery and intra-operative imaging systems. Its Diabetes Group segment provides insulin pumps; continuous glucose monitoring systems; insulin pump consumables; and Web-based therapy management software solutions. It serves hospitals, physicians, clinicians, and patients. Medtronic plc was founded in 1949 and is headquartered in Dublin, Ireland.

92,500 Employees
Last Reported Date: 06/23/15
Founded in 1949

medtronic plc (MDT) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $829.0K
Executive Vice President and Group President ...
Total Annual Compensation: $1.4M
Executive Vice President and Group President ...
Total Annual Compensation: $747.6K
Chief Human Resources Officer and Senior Vice...
Total Annual Compensation: $781.7K
Compensation as of Fiscal Year 2015.

medtronic plc (MDT) Key Developments

Medtronic plc Launches CD HORIZON(R) SOLERA(R) VOYAGER(TM) Spinal System

Medtronic plc announced the launch of the CD HORIZON(R) SOLERA(R) VOYAGER(TM) spinal system for Minimally Invasive Spine procedures. Available now in countries around the world, the CD HORIZON(R) SOLERA(R) VOYAGER(TM) System expands upon the transforaminal lumbar interbody fusion (TLIF) procedure by offering multiple, minimally invasive rod insertion options and enabling a seamless 3D-navigated surgical experience. With the CD HORIZON(R) SOLERA(R) VOYAGER(TM) System, surgeons have the flexibility to use either a percutaneous or Wiltse minimally invasive approach for rod insertion depending upon their preference. The system also features a low-profile, extended-tab screw with inner threading, which eases rod insertion and facilitates rod reduction. In addition, the system is part of Medtronic's Surgical Synergy(TM) Spinal Platform - the most integrated portfolio of navigated surgical technologies - which seeks to minimize the operating room from interruption and constraints and gives surgeons the freedom to focus wholly on their patients.

Medtronic plc Announces the Twelve-Month Results of the Veclose Pivotal Study

Medtronic plc announced the twelve-month results of the VeClose pivotal study, which demonstrated the safety and effectiveness of the VenaSeal(TM) closure system for the treatment of incompetent greater saphenous veins with a 96.8% closure rate. The VenaSeal closure system is a unique, minimally invasive, non-tumescent, non-thermal and non-sclerosant procedure that uses an advanced medical adhesive to close the diseased vein in patients with symptomatic venous reflux disease. Unlike other treatments, the VenaSeal closure system does not require tumescent anesthesia, allowing patients to return to their normal activities following the procedure. The VenaSeal procedure also eliminates the risk of nerve or other heat-related injury associated with thermal-based procedures, and may reduce the need for compression stockings post-procedure. The 12 month results of the VeClose study demonstrated outcomes for the VenaSeal closure system comparable with the closure rates associated with the ClosureFastTM catheter and demonstrated non-inferiority of the VenaSeal closure system.

U.S. Food and Drug Administration Approves Commercial Launch of the Advisa SR MRI(TM) SureScan(R) Single-Chamber Pacemaker with the 5076 MRI Lead

Medtronic plc announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of the Advisa SR MRI(TM) SureScan(R) single-chamber pacemaker with the 5076 MRI lead, which allows for magnetic resonance imaging (MRI) scans positioned on any region of the body without restrictions. The new system includes the Advisa SR MRI pacemaker and a SureScan lead, which must be used together to be considered MR-conditional. In addition to delivering single chamber pacing with the same SureScan(R) technology used in other Medtronic cardiac devices, the new Advisa SR MRI(TM) pacemaker has improved diagnostic information and storage, and a 35% improvement in battery longevity (when compared to the Adapta(R) single chamber pacing system). The Advisa single chamber pacemaker is the latest addition to a growing number of Medtronic devices that are designed for MRI access including the Advisa DR MRI(R) and Revo MRI(R) dual chamber SureScan pacing systems, the Reveal LINQ(R)Insertable Cardiac Monitoring (ICM) system, SureScan neurostimulation systems and the SynchroMed(R) II programmable drug infusion system which are available worldwide.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT:US $78.00 USD -0.39

MDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $69.73 USD -0.28
Amgen Inc $175.59 USD -1.00
Bristol-Myers Squibb Co $65.34 USD -0.30
Celgene Corp $131.47 USD +0.22
Eli Lilly & Co $84.14 USD -0.37
View Industry Companies

Industry Analysis


Industry Average

Valuation MDT Industry Range
Price/Earnings 32.5x
Price/Sales 5.5x
Price/Book 2.1x
Price/Cash Flow 32.5x
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDTRONIC PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at